Chemotherapy Induced Peripheral Neuropathy Market Forecast to 2028 , Pharmaceuticals

Chemotherapy Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Steroids, Antidepressants, Anti-Seizure, and Narcotics) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy)

Report Code : TIPRE00028941 | Region : Global | Industry : Pharmaceuticals | Published Date : 13/May/2022

The chemotherapy-induced peripheral neuropathy market is expected to grow from US$ 813.48 million in 2021 to US$ 1,174.26 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2021 to 2028.

The report highlights trends prevailing in the market and factors driving the chemotherapy-induced peripheral neuropathy market growth. The market growth is attributed to a rise in demand for cancer drugs and the use of chemotherapy in earlier stages. However, a lack of awareness regarding the symptoms of chemotherapy-induced peripheral neuropathy limits the market growth.

Peripheral neuropathy is indicated by symptoms that result from damage to the peripheral nerves. These nerves carry sensations, and control arm and leg movements as well as bladder and intestine functions. Chemotherapy and other medications used to treat cancer can cause peripheral neuropathy, which is termed as chemotherapy-induced peripheral neuropathy.

Spending on anticancer drugs is one of the most important factors incurring excess costs in healthcare. Both, chemotherapy and targeted therapy significantly improve the chances of survival among cancer patients, along with improving their quality of life. These therapies may result in the complete remission of a tumor. Owing to these benefits, the demand for chemotherapy has surged globally with the rising burden of cancer. A study published recently in Lancet Oncology states that the number of patients requiring chemotherapy will increase by 53% from 980,000 to 15 million worldwide from 2018 to 2040. Advanced cancer treatments further improve patient survival and increase the number of patients requiring long-term outpatient chemotherapy. More exposure to chemotherapy may result in a greater number of CIPN cases, thereby deriving the chemotherapy-induced peripheral neuropathy market growth.

Based on drug class, the chemotherapy-induced peripheral neuropathy market is segmented into steroids, anti-seizure, narcotics, and anti-depressants. In 2021, the steroids segment held the largest share of the market. However, the anti-seizure segment is expected to register the highest CAGR from 2021 to 2028. Based on distribution channel, the chemotherapy-induced peripheral neuropathy market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2021. However, the retail pharmacies segment is anticipated to register the highest CAGR during the forecast period.

COVID-19 Impact – Chemotherapy-Induced Peripheral Neuropathy Market

The COVID-19 pandemic had a major impact on oncology services at a global level during 2020–2021. It disrupted cancer treatment plans as many healthcare providers had to postpone the diagnosis and treatment of cancer cases. Moreover, social restrictions and lockdown measures resulted in the discontinuation of clinical trials.. Further, with the rise in COVID-19 burden, healthcare authorities had to conduct reprofiling of many hospitals and departments, including oncology clinics, for treating a large volume of patients. For Instance, in the Netherlands, cancer registry data show a significant reduction in cancer diagnosis compared to before the outbreak of COVID-19. In the UK, emergency referrals from primary care for people with suspected cancer reduced by 76%, and chemotherapy appointments for cancer patients decreased by 60% compared to the pre-COVID-19 levels. In France, the number of cancer diagnoses decreased by 35–50% in April 2020 compared to April 2019. As a result, disruptions in healthcare operations hampered the growth of the chemotherapy induced peripheral neuropathy market progress in 2020, due to the low number of chemotherapy sessions conducted during this period.

Various organic and inorganic strategies are adopted by companies in the chemotherapy-induced peripheral neuropathy market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the chemotherapy-induced peripheral neuropathy market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players in strengthening their customer base and expanding their product portfolios. A few of the significant developments by key players in the chemotherapy-induced peripheral neuropathy market are listed below.

• In April 2021, WEX Pharmaceuticals Inc. announced that two clinical trials on tetrodotoxin (TTX) as a therapeutic agent had been published in a special issue of the Toxins Journal. The cardiac safety study "Safety, Tolerability, Pharmacokinetics, and Concentration-QTc Analysis of Tetrodotoxin: A Randomized, Dose Escalation Study in Healthy Adults" was included in the special edition of the Toxins Journal, as was the study "Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding WEX.”

• In December 2020, Regenacy announced a joint venture with 3E Bioventures for the development of ricolinostat in China, which will be followed by a US-based phase 2 study in patients with painful diabetic peripheral neuropathy and other peripheral neuropathies. BC Regenacy’s lead program will evaluate the efficacy and safety of ricolinostat in patients with chemotherapy-induced peripheral neuropathy in China.

A few of the major primary and secondary sources referred to while preparing the report on the chemotherapy-induced peripheral neuropathy market are the World Health Organization (WHO), the Centers for Disease Control (CDC), and the Association of the British Pharmaceutical Industry (ABPI).

Rising Prevalence of Cancer Drives Chemotherapy-Induced Peripheral Neuropathy Market Growth

According to our new research study on “Chemotherapy-Induced Peripheral Neuropathy Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Drug Class and Distribution Channel,” the market is expected to grow from US$ 813.48 million in 2021 to US$ 1,174.26 million by 2028; it is estimated to grow at a CAGR of 5.4% during 2021–2028. The growth of the chemotherapy-induced peripheral neuropathy market is mainly driven by an increase in the prevalence of cancer and a rising preference for chemotherapy. Additionally, the growing number of clinical trials for chemotherapeutic drugs is likely to emerge as a significant trend in the market during the forecast period. However, the lack of consolidated guidelines for chemotherapy hampers the chemotherapy-induced peripheral neuropathy market growth.

Chemotherapy-induced peripheral neuropathy is one of the most frequent side effects caused by antineoplastic agents. Clinically, it is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, chemotherapy-induced peripheral neuropathy constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing it; moreover, the possibilities of treating this syndrome are limited.

Cancer is a leading cause of death worldwide. According to the World Health Organization (WHO), cancer was reported as the first leading cause of death in the people of age below 70 years in 183 countries and the fourth leading cause of death among the population of all ages in 123 countries worldwide in 2019. In addition, as per the data published by the WHO in March 2021, different cancer types caused ~10 million deaths in 2020.

The increasing prevalence of cancer has created a burden on healthcare systems across the world, along with bolstering the demand for chemotherapy. Chemotherapy-induced peripheral neuropathy is a common adverse effect of neurotoxic anticancer drugs, such as platinum-derivative drugs (cisplatin and oxaliplatin), spindle poisons [taxanes (paclitaxel and docetaxel), vinca alkaloids, vincristine, epothilones, and eribulin], bortezomib, and thalidomide. The high prevalence of chemotherapy-induced peripheral neuropathy raises concerns about cancer patients and survivors, and their healthcare providers, especially because there is no single effective way to prevent this condition.

In a study conducted by “The Journal of the International Association for the Study of Pain,” chemotherapy-induced peripheral neuropathy prevalence was reported at 68.1% (57.7–78.4 when measured in the first month after chemotherapy, 60.0% (36.4–81.6) in the third month, and 30.0% (6.4–53.5) in the sixth month or later. Thus, the growing incidence of chemotherapy-induced peripheral neuropathy with the increasing prevalence of cancer boosts the growth of the chemotherapy-induced peripheral neuropathy market.

Spending on anticancer drugs is one of the most important factors incurring excess costs in healthcare. Both, chemotherapy and targeted therapy significantly improve the chances of survival among cancer patients, along with improving their quality of life. These therapies may result in the complete remission of a tumor. Owing to these benefits, the demand for chemotherapy has surged globally with the rising burden of cancer. A study published recently in Lancet Oncology states that the number of patients requiring chemotherapy will increase by 53% from 980,000 to 15 million in the world from 2018 to 2040. However, the growing exposure to chemotherapy may result in a greater number of CIPN cases, which can be associated with the progress in the chemotherapy-induced peripheral neuropathy market.

Regenacy Pharmaceuticals, Inc.; Asahi Kasei Pharma Corporation; Novaremed; Makscientific, Llc; Wex Pharmaceuticals Inc.; Sova Pharmaceuticals, Inc.; Kineta, Inc.; Aptinyx Inc.; Apexian Pharmaceuticals, Inc.; and Winsantor, Inc. are among the leading companies operating in the chemotherapy induced peripheral neuropathy market. Product launches, product approvals, mergers and acquisitions, and market initiatives are a few strategies adopted by the major market player. For instance, in December 2020, Regenacy Pharmceutical, Inc. announced a joint venture with 3E Bioventures for the development of ricolinostat in China, which will be followed by a US-based phase 2 study in patients with painful diabetic peripheral neuropathy and other peripheral neuropathies. BC Regenacy’s lead program will evaluate the efficacy and safety of ricolinostat in patients with chemotherapy-induced peripheral neuropathy in China.

Chemotherapy Induced Peripheral Neuropathy Market, by Region, 2021 (%)

Source: The Insight Partners Analysis

The chemotherapy-induced peripheral neuropathy market is segmented on the basis of drug class, distribution channel, and geography. The market, by drug class, is segmented into steroids, antidepressants, anti-seizures, and narcotics. The chemotherapy-induced peripheral neuropathy market, based on distribution channel, is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the chemotherapy-induced peripheral neuropathy market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Market – By Drug Class

1.3.2 Global Chemotherapy Induced Peripheral Neuropathy Market – By Distribution Channel

1.3.3 Global Chemotherapy Induced Peripheral Neuropathy Market – By Geography

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Chemotherapy Induced Peripheral Neuropathy Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America PEST Analysis

4.2.2 Europe PEST Analysis

4.2.3 Asia Pacific PEST Analysis

4.2.4 Middle East And Africa PEST Analysis

4.2.5 South And Central America PEST Analysis

4.3 Experts Opinion

5. Chemotherapy Induced Peripheral Neuropathy Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increasing Prevalence of Cancer

5.1.2 Increasing Preference for Chemotherapy

5.2 Market Restraints

5.2.1 Lack of Consolidated Guidelines for Chemotherapy

5.3 Market Opportunities

5.3.1 Emerging Markets in Developing Countries

5.4 Future Trends

5.4.1 Rising Clinical Trails for Chemotherapeutic Drugs

5.5 Impact Analysis

6. Chemotherapy Induced Peripheral Neuropathy Market– Global Analysis

6.1 Global Chemotherapy Induced Peripheral Neuropathy Market Revenue Forecast And Analysis

6.1.1 Global Chemotherapy Induced Peripheral Neuropathy Market Revenue Forecast And Analysis

6.1.2 Global Chemotherapy Induced Peripheral Neuropathy Market – Market Potential Analysis, By Region

6.2 Market Positioning Analysis Of Key Players In Chemotherapy Induced Peripheral Neuropathy Market

6.2.1 Company Analysis

6.2.2 Growth Strategy Analysis

6.2.3 Performance Of Key Players

6.2.3.1 Wex Pharmaceuticals Inc.

6.2.3.2 Regenacy Pharmaceuticals, Inc.

7. Global Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts To 2028– by Drug Class

7.1 Overview

7.2 Drug Class Market Revenue and Forecast Analysis (US$ Mn)

7.3 Steroids

7.3.1 Overview

7.3.2 Steroids Revenue and Forecast to 2028 (US$ Mn)

7.4 Antidepressants

7.4.1 Overview

7.4.2 Antidepressants Revenue and Forecast to 2028 (US$ Mn)

7.5 Anti-seizure Error! Bookmark not defined.

7.5.1 Overview

7.5.2 Anti-seizure Revenue and Forecast to 2028 (US$ Mn)

7.6 Narcotics

7.6.1 Overview

7.6.2 Narcotics Revenue and Forecast to 2028 (US$ Mn)

8. Global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Analysis and Forecast to 2028 – by Distribution Channel

8.1 Overview

8.2 Distribution Channel Market Revenue and Forecast Analysis (US$ Mn)

8.3 Hospital Pharmacy

8.3.1 Overview

8.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

8.4 Retail Pharmacy

8.4.1 Overview

8.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

8.5 Online Pharmacy

8.5.1 Overview

8.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9. Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 – Geographical Analysis

9.1 North America: Chemotherapy Induced Peripheral Neuropathy Market

9.1.1 Overview

9.1.2 North America: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.3 North America: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.1.4 North America: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.1.5 North America: Chemotherapy Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)

9.1.5.1 US: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.1.1 US: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.1.2 US: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.1.5.1.3 US: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.1.5.2 Canada: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.2.1 Canada: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.2.2 Canada: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.1.5.2.3 Canada: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.1.5.3 Mexico: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.3.1 Mexico: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.3.2 Mexico: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.1.5.3.3 Mexico: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2 Europe: Chemotherapy- Induced Peripheral Neuropathy Market

9.2.1 Overview

9.2.2 Europe: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)

9.2.3 Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.4 Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2.5 Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)

9.2.5.1 Germany: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.1.1 Germany: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.1.2 Germany: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.5.1.3 Germany: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2.5.2 France: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.2.1 France: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.2.2 France: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.5.2.3 France: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2.5.3 UK: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.3.1 UK: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.3.2 UK: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.5.3.3 UK: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2.5.4 Italy: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.4.1 Italy: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.4.2 Italy: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.5.4.3 Italy: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2.5.5 Spain: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.5.1 Spain: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.5.2 Spain: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.5.5.3 Spain: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2.5.6 Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.6.1 Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.6.2 Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.5.6.3 Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.3 Asia Pacific: Chemotherapy- Induced Peripheral Neuropathy Market

9.3.1 Overview

9.3.2 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.3 Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.4 Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

9.3.5 Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Country (%)

9.3.5.1 Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.1.1 Overview

9.3.5.1.2 Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.1.3 Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.5.1.4 Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

9.3.5.2 China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.2.1 Overview

9.3.5.2.2 China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.2.3 China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.5.2.4 China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

9.3.5.3 India Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.3.1 Overview

9.3.5.3.2 India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.3.3 India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.5.3.4 India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

9.3.5.4 South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.4.1 Overview

9.3.5.4.2 South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.4.3 South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.5.4.4 South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

9.3.5.5 Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.5.1 Overview

9.3.5.5.2 Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.5.3 Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.5.5.4 Australia: Chemotherapy Induced Peripheral Neuropathy Market, by Sub-Drug Class, 2019–2028 (US$ Million)

9.3.5.6 Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.3.5.6.1 Overview

9.3.5.6.2 Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.3.5.6.3 Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.5.6.4 Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

9.4 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market

9.4.1 Overview

9.4.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)

9.4.3 Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Product (US$ Million)

9.4.4 Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

9.4.5 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Country (%)

9.4.5.1 UAE: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.1.1 UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.1.2 UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

9.4.5.1.3 UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

9.4.5.2 Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.2.1 Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.2.2 Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

9.4.5.2.3 Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

9.4.5.3 South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.3.1 South Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.3.2 South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

9.4.5.3.3 South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

9.4.5.4 Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.4.1 Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.4.2 Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

9.4.5.4.3 Rest of Middle East & Africa: D Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

9.5 South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market

9.5.1 Overview

9.5.2 South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.3 South and Central America Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

9.5.4 South and Central America Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

9.5.5 South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)

9.5.5.1 Brazil: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.5.2 Brazil: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.5.2.1 Brazil Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

9.5.5.2.2 Brazil Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

9.5.5.3 Argentina: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.5.3.1 Argentina: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.5.3.2 Argentina Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

9.5.5.3.3 Argentina Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

9.5.5.4 Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.5.4.1 Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.5.4.2 Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

9.5.5.4.3 Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

10. Impact Of COVID-19 Pandemic on Chemotherapy Induced Peripheral Neuropathy Market

10.1 North America: Impact Assessment of COVID-19 Pandemic

10.2 Europe: Impact Assessment of COVID-19 Pandemic

10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic

10.5 South and Central America: Impact Assessment of COVID-19 Pandemic

11. Chemotherapy Induced Peripheral Neuropathy Market– Industry Landscape

11.1 Overview

11.2 Growth Strategies Done by the Companies in the Market, (%)

11.3 Organic Developments

11.3.1 Overview

11.4 Inorganic Developments

11.4.1 Overview

12. Company Profiles

12.1 REGENACY PHARMACEUTICALS, INC.

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Asahi Kasei Pharma Corporation

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Novaremed AG

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 MAKScientific, LLC

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 WEX Pharmaceuticals Inc.

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Sova Pharmaceuticals, Inc.

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 Kineta, Inc.

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 Aptinyx Inc.

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

12.9 Apexian Pharmaceuticals, Inc.

12.9.1 Key Facts

12.9.2 Business Description

12.9.3 Products and Services

12.9.4 Financial Overview

12.9.5 SWOT Analysis

12.9.6 Key Developments

12.10 WinSanTor, Inc.

12.10.1 Key Facts

12.10.2 Business Description

12.10.3 Financial Overview

12.10.4 SWOT Analysis

12.10.5 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms

LIST OF TABLES.

Table 1. North America Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 2. North America Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 3. US Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 4. US Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 5. Canada: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 6. Canada Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 7. Mexico: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 8. Mexico Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 9. Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 10. Europe Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 11. Germany: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 12. Germany: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 13. France: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 14. France: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 15. UK: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 16. UK: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 17. Italy: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 18. Italy: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 19. Spain: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 20. Spain: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 21. Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 22. Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 23. Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million).

Table 24. Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

Table 25. Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

Table 26. Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

Table 27. China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

Table 28. China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

Table 29. India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

Table 30. India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

Table 31. South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

Table 32. South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

Table 33. Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

Table 34. Australia: Chemotherapy Induced Peripheral Neuropathy Market, by Sub-Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 35. Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

Table 36. Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

Table 37. Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Product (US$ Million)

Table 38. Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

Table 39. UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

Table 40. UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

Table 41. Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

Table 42. Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

Table 43. South Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

Table 44. South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 45. Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

Table 46. Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 47. South and Central America Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 48. South and Central America Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 49. Brazil Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 50. Brazil Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 51. Argentina Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 52. Argentina Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 53. Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 54. Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 55. Organic Developments Done By Companies

Table 56. Inorganic Developments Done By Companies

Table 57. Glossary of Terms

LIST OF FIGURES.

Figure 1. Chemotherapy Induced Peripheral Neuropathy Market Segmentation

Figure 2. Chemotherapy Induced Peripheral Neuropathy Market, By Region

Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Market Overview

Figure 4. Steroids Segment Held Largest Share of Drug Class Segment in Chemotherapy Induced Peripheral Neuropathy Market

Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period

Figure 6. Chemotherapy Induced Peripheral Neuropathy Market, by Geography (US$ Million)

Figure 7. Global Chemotherapy Induced Peripheral Neuropathy Market - Leading Country Markets (US$ Million)

Figure 8. Global Chemotherapy Induced Peripheral Neuropathy Market, Industry Landscape

Figure 9. North America: PEST Analysis

Figure 10. Europe: PEST Analysis

Figure 11. Asia Pacific: PEST Analysis

Figure 12. Middle East And Africa: PEST Analysis

Figure 13. South And Central America: PEST Analysis

Figure 14. Experts Opinion

Figure 15. Most Prevalent Forms of Cancers in the World, 2020

Figure 16. Impact Analysis of Drivers and Restraints Pertaining to Chemotherapy Induced Peripheral Neuropathy Market

Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Market– Revenue Forecast And Analysis – 2020- 2028

Figure 18. Global Chemotherapy Induced Peripheral Neuropathy Market– Revenue Forecast And Analysis – 2021 - 2028

Figure 19. Global Chemotherapy Induced Peripheral Neuropathy Market – Market Potential Analysis, By Region

Figure 20. Market Positioning Analysis Of Key Players In Global Chemotherapy Induced Peripheral Neuropathy Market

Figure 21. Global Chemotherapy Induced Peripheral Neuropathy Market – Comparative Company Analysis

Figure 22. Global Chemotherapy Induced Peripheral Neuropathy Market – Growth Strategy Analysis

Figure 23. Drug Class Market Analysis and Forecast 2021 and 2028 (%)

Figure 24. Steroids Revenue and Forecast to 2028 (US$ Mn)

Figure 25. Antidepressants Revenue and Forecast to 2028 (US$ Mn)

Figure 26. Anti-seizure Revenue and Forecast to 2028 (US$ Mn)

Figure 27. Narcotics Revenue and Forecast to 2028 (US$ Mn)

Figure 28. Distribution Channel Market Analysis and Forecast 2021 and 2028 (%)

Figure 29. Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 30. Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 31. Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 32. North America: Chemotherapy Induced Peripheral Neuropathy Market, by Key Country – Revenue (2021) (US$ Million)

Figure 33. North America Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)

Figure 34. North America: Chemotherapy Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)

Figure 35. US: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36. Canada: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37. Mexico: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 38. Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Key Country – Revenue (2021) (US$ Million)

Figure 39. Europe Chemotherapy- Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)

Figure 40. Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)

Figure 41. Germany: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 42. France: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 43. UK: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 44. Italy: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 45. Spain: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 46. Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 47. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Market Overview, by Country (2021)

Figure 48. Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

Figure 49. Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Country (%)

Figure 50. Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

Figure 51. China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

Figure 52. India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

Figure 53. South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

Figure 54. Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

Figure 55. Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 56. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue Overview, by Country, 2021 (US$ Million)

Figure 57. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

Figure 58. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Country (%)

Figure 59. UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

Figure 60. Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

Figure 61. South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

Figure 62. Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

Figure 63. South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Key Country – Revenue (2021) (USD Million)

Figure 64. South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (USD Million)

Figure 65. South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)

Figure 66. Brazil: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

Figure 67. Argentina: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

Figure 68. Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

Figure 69. Impact of COVID-19 Pandemic in North American Country Markets

Figure 70. Impact of COVID-19 Pandemic in European Country Markets

Figure 71. Impact of COVID-19 Pandemic in Asia Pacific Country Markets

Figure 72. Impact of COVID-19 Pandemic in Middle East & Africa Country Markets

Figure 73. Impact of COVID-19 Pandemic on Chemotherapy- Induced Peripheral Neuropathy Market in South and Central American Countries

Figure 74. Growth Strategies Done by the Companies in the Market, (%)

The List of Companies - Chemotherapy Induced Peripheral Neuropathy Market

1. REGENACY PHARMACEUTICALS, INC

2. ASAHI KASEI PHARMA CORPORATION

3. NOVAREMED

4. MAKSCIENTIFIC, LLC

5. WEX PHARMACEUTICALS INC

6. SOVA PHARMACEUTICALS, INC

7. KINETA, INC.

8. APTINYX INC.

9. APEXIAN PHARMACEUTICALS, INC.

10. WINSANTOR, INC

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the chemotherapy- induced peripheral neuropathy market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the global chemotherapy- induced peripheral neuropathy market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Back to Industry Report

Pricing
	$4,550.00	Single User Price
	$6,550.00	Site Price
	$8,550.00	Enterprise Price
Buy Now

Chemotherapy Induced Peripheral Neuropathy Market Forecast to 2028

Have Additional Questions?